I.E.R.F.C. European Institute for Cystic Fibrosis Research
发明人:
申请号：
EP12168409.6
公开号：
EP2664326B1
申请日:
2012.05.17
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ”F508-CFTR mutation, and pharmaceutical compositions thereof.
